(PharmaNewsWire.Com, April 24, 2017 ) Browse 176 market data tables and 33 figures spread through 184 pages and in-depth TOC on “Cardiac Monitoring & Cardiac Rhythm Management Devices Market”
Early buyers will receive 10% customization on this report.
Factors such as increasing incidence of cardiovascular diseases, technological advancements, and rise in private institutional nursing and home care are driving the CM & CRM devices market. However, dearth of skilled healthcare professionals with expertise in electrocardiography and cardiac monitoring and limited reimbursements for remote cardiac monitoring devices are major factors restraining the growth of the CM & CRM devices market.
The market is segmented on the basis of product, end user, and region. On the basis of product, the CM devices market is segmented into ECG devices, implantable loop recorder (ILR), and cardiac output monitoring (COM) devices, and event monitors. The ECG devices segment is the largest and fastest-growing product segment due to increasing incidence of cardiovascular diseases.
On the basis of product, the CRM devices market is segmented into defibrillators, pacemakers, and cardiac resynchronization therapy (CRT) devices. The defibrillators segment is the largest and fastest-growing segment.
On the basis of end user, the market is segmented into home and ambulatory care, hospitals, and other end users (research institutes and laboratories). The home and ambulatory care segment is expected to account for the largest share of the market in 2016.
On the basis of region, the CM & CRM devices market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2015, North America accounted for the largest share of the CM & CRM devices market, followed by Europe. However, Asia is expected to account for the largest share during the forecast period. The growth of the CM & CRM devices market in the Asia will revolve around China, India, and Japan.
Major players operating in the CM & CRM devices market are Medtronic plc (Ireland), GE Healthcare (U.S.), Boston Scientific Corporation (U.S.), Philips Healthcare (Netherlands), and St. Jude Medical, Inc. (U.S.)
About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
